

# Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/C535CCF9254EN.html>

Date: March 2018

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: C535CCF9254EN

## Abstracts

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

### SUMMARY

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. The latest report Collagenase 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Toxicology, Central Nervous System, Infectious Disease and Respiratory which include indications Osteoarthritis, Chemotherapy Induced Peripheral Neuropathy, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Collagenase 3 (Matrix

Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

## Contents

Introduction

Global Markets Direct Report Coverage

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies

Involved in Therapeutics Development

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Takeda Pharmaceutical Co Ltd

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-152 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZF-198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZF-760 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones

Featured News & Press Releases

Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%

Jan 24, 2018: Current and past elite sportspeople successfully treated with PPS

Jan 16, 2018: European Patent Granted for Bone Marrow Edema Lesions

Nov 23, 2017: Paradigm's Two Arthritis Phase 2 Clinical Trials on Schedule

Nov 14, 2017: Paradigm Reports Successful Phase 2a BML/ACL Clinical Trial Results

Oct 30, 2017: First Participant Successfully Dosed in Phase 2b Clinical Trial for Osteoarthritis

Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis

Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial

Sep 11, 2017: A Paradigm Shift in Treating Osteoarthritis Pain

Aug 09, 2017: Paradigm Successfully Doses First Participant in Phase 2 Ross River Virus Clinical Trial

Jul 10, 2017: Paradigm to Commence Phase 2 Ross River Virus Clinical Trial

May 16, 2017: Paradigm's preclinical hay fever trial: peer-reviewed and published in leading scientific journal

Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial

Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River

Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Takeda Pharmaceutical Co Ltd



## I would like to order

Product name: Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/C535CCF9254EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C535CCF9254EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

